Cardiovascular

VTE: duration of anticoagulation and provoked vs unprovoked decisions

Clinical Overview and When to Suspect VTE Recurrence Risk

— Provoked: VTE occurring within ~3 months of a transient or persistent risk factor.

— Unprovoked (idiopathic): no identifiable trigger; carries ~10% recurrence at 1 year and ~30% at 5 years off therapy.

— A patient completes 3 months of anticoagulation for a first VTE.

— A patient develops a second VTE on or off therapy.

— Cancer therapy ends or remits.

— Antiphospholipid syndrome (APS) testing returns positive.

— Bleeding occurs on therapy, forcing reassessment.

Board pearl: All VTE patients receive a minimum of 3 months of anticoagulation. The decision after 3 months is the testable inflection point — extension beyond 3 months requires affirmative justification (unprovoked, cancer, persistent risk factor, APS, or recurrent event).

Key distinction: "Provoked by major transient factor" (surgery >30 min, hospitalization ≥3 days, major trauma, cesarean) → stop at 3 months. "Provoked by minor transient factor" (estrogen, long-haul flight, leg injury without immobilization, pregnancy/postpartum without other risks) → still typically 3 months but with closer recurrence surveillance. "Persistent provoking factor" (active cancer, IBD flare, immobility) → extend while factor persists.

Venous thromboembolism (VTE) encompasses deep vein thrombosis (DVT) and pulmonary embolism (PE); the central Step 3 decision after acute treatment is how long to anticoagulate.

Duration hinges on a single conceptual axis: provoked vs unprovoked, modified by bleeding risk, cancer status, and thrombophilia.

Suspect a recurrence-risk decision point whenever:

Epidemiology: ~1–2 per 1000 person-years; recurrence drives long-term morbidity (post-thrombotic syndrome in 20–50% of DVT, chronic thromboembolic pulmonary hypertension in 2–4% of PE).

Step 3 framing: the question is rarely "does this patient have VTE?" but rather "after 3 months, do you stop, continue indefinitely, or change agents?"

Presentation Patterns and Key History

— Date of diagnosis, anatomic extent (distal vs proximal DVT, segmental vs subsegmental PE, saddle PE), and hemodynamic severity.

— Events in the 90 days before the clot: surgery, hospitalization, immobility >3 days, trauma, long travel (>8 hr), pregnancy/postpartum (within 12 weeks).

— Hormonal exposure: estrogen-containing OCPs, HRT, tamoxifen, testosterone.

— Active malignancy or chemotherapy.

— Family history of VTE in first-degree relatives <50 years (suggests hereditary thrombophilia).

— Prior GI bleed, intracranial hemorrhage, menorrhagia requiring intervention.

— Falls (≥2 in past year), frailty, alcohol use ≥8 drinks/week.

— NSAID or antiplatelet use, hepatic/renal impairment.

— Male sex (1.6× higher recurrence than female after unprovoked VTE).

— Residual vein obstruction on ultrasound.

— Elevated D-dimer 1 month after stopping anticoagulation.

— Prior VTE before the index event (automatically indefinite therapy).

Step 3 management: At the 3-month visit, structure the encounter as: (1) confirm provocation category, (2) HAS-BLED or VTE-BLEED score for bleeding risk, (3) shared decision-making conversation documented, (4) explicit plan — stop, continue full-dose, or step down to prophylactic-dose DOAC.

Board pearl: A patient with unprovoked PE who is male with elevated post-treatment D-dimer has recurrence risk >10%/year — strongly favor indefinite anticoagulation.

At the duration-decision visit, history determines provocation category and bleeding risk — not diagnosis.

Reconstruct the index event timeline:

Bleeding history:

Recurrence clues:

Symptom review at follow-up: new leg swelling, pleuritic chest pain, dyspnea on exertion (could signal CTEPH), heaviness/skin changes (post-thrombotic syndrome).

Medication reconciliation: confirm adherence; missed DOAC doses are a hidden recurrence driver.

Physical Exam Findings and Hemodynamic Assessment

— Loud P2, RV heave, tricuspid regurgitation murmur → CTEPH suspicion; obtain echocardiogram.

— Persistent dyspnea 3 months post-PE → V/Q scan (preferred over CT for CTEPH screening).

— Post-thrombotic syndrome (PTS): chronic edema, hyperpigmentation, venous eczema, ulcers in gaiter area. Quantify with Villalta score.

— Asymmetric calf swelling >3 cm → re-image with duplex (compare to baseline residual venous obstruction).

CCS pearl: On a CCS case of "follow-up after PE," advance the clock by 3 months and order: CBC, CMP, repeat D-dimer (if considering stopping), and clinical reassessment. Do not routinely order thrombophilia panels — they rarely change duration decisions.

Key distinction: Residual DVT on follow-up ultrasound independently predicts recurrence but is no longer recommended as a universal decision tool — use it selectively when the bleeding–clotting tradeoff is borderline.

Board pearl: New unilateral leg swelling on anticoagulation = breakthrough VTE — confirm with duplex, switch to LMWH (especially if cancer-associated), and investigate adherence and drug interactions before declaring "treatment failure."

The duration-decision exam is largely a bleeding and recurrence surveillance exam.

Vital signs: resting tachycardia or hypoxia raises concern for unresolved PE or CTEPH; hypertension on therapy increases ICH risk.

Cardiopulmonary:

Extremity exam:

Bleeding stigmata: petechiae, ecchymoses, occult blood on rectal exam if symptomatic; conjunctival pallor suggests occult anemia.

Frailty/fall risk: timed up-and-go, gait observation — older patients on indefinite anticoagulation need this documented.

Skin and joints: livedo reticularis, malar rash, arthralgias → screen for APS or SLE.

Abdomen: hepatomegaly, splenomegaly, or unexplained weight loss → occult malignancy workup; up to 10% of unprovoked VTE patients harbor cancer within 12 months.

Diagnostic Workup — Initial Labs and Imaging at the Decision Point

— CBC: baseline platelets and hemoglobin to track bleeding.

— CMP: creatinine (CrCl drives DOAC dosing), LFTs (hepatic dysfunction limits DOACs).

— PT/INR, aPTT: baseline before therapy; abnormal aPTT raises APS suspicion.

— D-dimer: at diagnosis confirms acute event; later, 1 month after stopping anticoagulation, a negative D-dimer in women supports stopping (HERDOO2 rule).

— Age-appropriate screening per USPSTF (mammography, colonoscopy, cervical, lung CT if eligible).

— History, exam, basic labs, CXR — limited screening, not extensive imaging.

— The SOME trial showed routine CT abdomen/pelvis did not improve outcomes.

— Generally not indicated because results rarely change management.

— Consider for: unprovoked VTE in young patients with strong family history, recurrent VTE, thrombosis at unusual sites (splanchnic, cerebral), or warfarin-induced skin necrosis.

— Test off anticoagulation ideally and away from acute event (≥3 months); DOACs and heparin affect lupus anticoagulant assays.

Board pearl: Triple-positive APS patients had higher recurrence on rivaroxaban than warfarin in the TRAPS trial — avoid DOACs in APS, especially triple-positive.

Step 3 management: Order APS testing before stopping anticoagulation in unprovoked VTE; a positive result flips the plan from "stop" to "indefinite warfarin (INR 2–3)."

At index VTE diagnosis (already established by CT-PA, V/Q, or compression ultrasound), the labs that drive duration rather than diagnosis are:

Cancer screening in unprovoked VTE:

Thrombophilia testing — when to do it:

Antiphospholipid syndrome (APS) screen — lupus anticoagulant, anti-cardiolipin, anti-β2 glycoprotein I — should be considered in unprovoked VTE in younger patients or those with autoimmune features, because APS mandates warfarin (not DOACs) and indefinite therapy.

Diagnostic Workup — Advanced or Confirmatory Studies

— Hyperpigmentation, edema, or redness of either leg

— D-dimer ≥250 µg/L on anticoagulation (or after stopping)

— Obesity (BMI ≥30)

— Older age (≥65)

— Score 0–1 → annual recurrence <3% → safe to stop after 3–6 months.

— Score ≥2 or any male → continue anticoagulation.

— RV dilation, elevated PASP → proceed to V/Q scan for CTEPH.

— V/Q scan is the screening test of choice for CTEPH; if positive, refer for right heart cath and CT pulmonary angiography.

— HAS-BLED (originally for AF, applied broadly): ≥3 = high risk.

— VTE-BLEED: VTE-specific; ≥2 points predicts major bleeding on extended therapy.

— Variables: active cancer, male with uncontrolled HTN, anemia, history of bleeding, age ≥60, renal dysfunction.

Key distinction: HERDOO2 applies only to women with first unprovoked VTE. Do not apply it to men — men with unprovoked VTE have a recurrence rate too high to justify stopping.

Board pearl: Persistent dyspnea >3 months after PE = screen for CTEPH with V/Q scan, not CT-PA. CTEPH is treatable with pulmonary thromboendarterectomy.

HERDOO2 rule (validated in women only) to identify low-risk unprovoked VTE for discontinuation:

DASH score and Vienna prediction model: alternative tools incorporating sex, D-dimer, age, and hormonal trigger. Less commonly tested but useful adjuncts.

Repeat compression ultrasound at 3 months establishes a new baseline for future suspected recurrence (residual venous obstruction).

Echocardiogram at 3–6 months post-PE if persistent dyspnea or functional limitation:

Bleeding risk scores:

Subsegmental PE without DVT: in low-risk patients, surveillance with serial ultrasound (no anticoagulation) is acceptable per ACCP — this is a tested nuance.

Risk Stratification: The Provoked vs Unprovoked Decision Logic

— Major transient provocation (surgery >30 min with general anesthesia, hospitalization ≥3 days with acute illness, cesarean): recurrence <1%/year → 3 months total.

— Minor transient provocation (estrogen, pregnancy, leg injury, flight >8 hr): recurrence ~3%/year → 3 months, reassess.

— Unprovoked: recurrence ~10%/year → consider indefinite.

— Persistent provoking factor (active cancer, IBD, immobility): indefinite while factor persists.

— Recurrent unprovoked VTE: indefinite.

— Low: <2%/year → favor extension.

— Moderate: 2–8%/year → individualize.

— High: >8%/year → favor stopping or reduced-dose DOAC.

— Discuss recurrence vs bleeding tradeoff explicitly.

— Document the conversation.

— Reduced-dose DOAC after 6 months: apixaban 2.5 mg BID or rivaroxaban 10 mg daily — non-inferior efficacy with less bleeding (AMPLIFY-EXT, EINSTEIN-CHOICE).

— Full-dose DOAC if high recurrence risk (cancer, APS exception).

— Warfarin INR 2–3 for APS or mechanical valves.

— Aspirin 100 mg daily: inferior to DOACs but better than nothing if refusing anticoagulation.

Step 3 management: A 45-year-old man with unprovoked PE completing 6 months of apixaban 5 mg BID → step down to apixaban 2.5 mg BID indefinitely; reassess yearly.

Board pearl: "Persistent risk factor" (active cancer, antiphospholipid syndrome, indwelling catheter, IBD flare) trumps the 3-month rule — anticoagulate as long as the factor persists.

Step 1 — Categorize the index event:

Step 2 — Assess bleeding risk (VTE-BLEED or clinical judgment):

Step 3 — Patient preference and shared decision-making:

Step 4 — Choose regimen for extended therapy:

Pharmacotherapy — First-Line Regimens and Duration Choices

— 10 mg BID × 7 days → 5 mg BID × 6 months → 2.5 mg BID indefinitely if extended therapy chosen.

— Lowest bleeding rates among DOACs.

— Safe in CrCl ≥25 mL/min.

— 15 mg BID × 21 days → 20 mg daily × 6 months → 10 mg daily indefinitely.

— Take with food (especially the 15/20 mg doses for absorption).

— First-line for active cancer-associated thrombosis historically; now DOACs (apixaban, edoxaban, rivaroxaban) are preferred unless GI/GU cancer where bleeding risk is high.

— Used in pregnancy (DOACs and warfarin contraindicated).

— Indefinite means no defined stop date — reassess annually for bleeding risk, adherence, new comorbidities.

Board pearl: Reduced-dose apixaban (2.5 mg BID) or rivaroxaban (10 mg daily) after the initial 6 months for unprovoked VTE maintains ~80% recurrence reduction with ~40% less major bleeding vs full dose.

Key distinction: Aspirin 100 mg daily reduces recurrence ~30% (WARFASA, ASPIRE) — use only when patient refuses anticoagulants; DOAC > aspirin by a wide margin.

DOACs are first-line for most VTE (apixaban, rivaroxaban, edoxaban, dabigatran).

Apixaban:

Rivaroxaban:

Edoxaban: requires 5–10 days of parenteral lead-in (LMWH or UFH), then 60 mg daily (30 mg if CrCl 15–50 or weight ≤60 kg).

Dabigatran: 5–10 days LMWH lead-in, then 150 mg BID; has a reversal agent (idarucizumab).

Warfarin (INR 2–3): required for APS, mechanical valves, severe renal impairment (CrCl <15), and remains an option for cost-sensitive patients. Bridge with LMWH until INR therapeutic for 2 consecutive days.

LMWH (enoxaparin 1 mg/kg BID or 1.5 mg/kg daily):

Extended therapy duration:

Special Scenarios — Cancer, APS, and Site-Specific VTE

— Apixaban, edoxaban, or rivaroxaban preferred for most cancers (CARAVAGGIO, Hokusai-VTE Cancer, SELECT-D).

— LMWH preferred in luminal GI cancer, GU cancer with intact tumor, severe thrombocytopenia, or significant drug interactions (e.g., tyrosine kinase inhibitors with rivaroxaban).

— Continue as long as cancer is active or chemotherapy ongoing — typically indefinite.

— Platelet count <50,000 → reduce dose or hold; <25,000 → hold.

— Warfarin INR 2–3 is standard; INR 3–4 if recurrent despite therapeutic INR or arterial events.

— DOACs contraindicated, especially triple-positive APS (lupus anticoagulant + anti-cardiolipin + anti-β2GPI).

— Indefinite anticoagulation.

— Anticoagulate ≥3 months; indefinite if unprovoked, cirrhosis with portal HTN, or myeloproliferative neoplasm (check JAK2).

— DOACs increasingly accepted; LMWH or warfarin if cirrhotic.

— Surveillance ultrasound × 2 weeks or anticoagulate 6 weeks–3 months.

— Full 3 months if severe symptoms, risk factors for extension, or unprovoked.

CCS pearl: For metastatic colon cancer + PE on chemotherapy, order enoxaparin 1 mg/kg SC BID or apixaban 10 mg BID × 7 days then 5 mg BID — avoid rivaroxaban if luminal GI tumor present.

Board pearl: JAK2 V617F mutation testing is indicated in unprovoked splanchnic vein thrombosis — myeloproliferative neoplasms are a frequent occult driver.

Cancer-associated thrombosis (CAT):

Antiphospholipid syndrome (APS):

Splanchnic vein thrombosis (portal, mesenteric, splenic, hepatic):

Cerebral venous thrombosis: anticoagulate 3–12 months; longer if persistent risk factor.

Catheter-associated upper extremity DVT: anticoagulate while catheter in place + 3 months after removal; remove catheter only if non-functional, infected, or symptoms persist.

Isolated distal (calf) DVT:

Special Populations — Elderly and Renal/Hepatic Impairment

— Recurrence risk and bleeding risk both rise; net benefit of extended therapy is narrower.

— Apixaban has the most favorable safety profile in elderly (AMPLIFY subgroup).

— Assess fall risk, polypharmacy, cognition, adherence — anticoagulation is rarely contraindicated by falls alone (a patient must fall ~295 times/year for fall-related ICH risk to outweigh stroke prevention benefit, by classic analysis).

— Reduced-dose extended therapy (apixaban 2.5 mg BID) is particularly attractive.

— CrCl ≥30 mL/min: all DOACs acceptable.

— CrCl 15–29: apixaban preferred; rivaroxaban and edoxaban with caution; avoid dabigatran.

— CrCl <15 or dialysis: warfarin preferred (apixaban has limited dialysis data; some guidelines permit apixaban 5 mg BID in ESRD, but this is controversial).

— Recalculate CrCl every 6–12 months and with acute illness.

— Child-Pugh A: all DOACs acceptable.

— Child-Pugh B: avoid rivaroxaban; apixaban and dabigatran with caution.

— Child-Pugh C: avoid all DOACs; use LMWH (with anti-Xa monitoring) or warfarin (difficult to manage due to baseline INR elevation).

— Strong CYP3A4/P-gp inhibitors (ketoconazole, ritonavir): avoid DOACs or reduce dose.

— Strong inducers (rifampin, phenytoin, carbamazepine, St. John's wort): avoid DOACs — efficacy drops sharply.

Step 3 management: For an 82-year-old woman with unprovoked PE, CrCl 28, on 7 medications → apixaban 5 mg BID × 6 months, then 2.5 mg BID indefinitely, with annual reassessment.

Key distinction: "Falls risk" alone is not a contraindication to anticoagulation — bleeding history and frailty trajectory matter more.

Elderly (≥75 years):

Renal impairment:

Hepatic impairment:

Drug interactions:

Special Populations — Pregnancy, Postpartum, and Hormonal Considerations

— LMWH (enoxaparin, dalteparin) is the standard — does not cross placenta, no fetal risk.

— Warfarin contraindicated (teratogenic, especially weeks 6–12; fetal warfarin syndrome).

— DOACs contraindicated — insufficient safety data, possible fetal exposure.

— Duration: full anticoagulation antepartum + at least 6 weeks postpartum, with total duration ≥3 months.

— Hold LMWH 24 hours before scheduled delivery; resume 12–24 hours post-vaginal delivery, 24 hours post-cesarean.

— VTE risk is highest in the first 6 weeks postpartum; pregnancy + 6-week window counts as a major transient provoking factor.

— A first VTE provoked by pregnancy/postpartum → 3 months total, no extension required.

— LMWH and warfarin are safe.

— DOACs not recommended (limited data, possible excretion).

— After a VTE, discontinue estrogen-containing contraceptives.

— Progestin-only methods (levonorgestrel IUD, progestin-only pill, etonogestrel implant) are safe.

— Restarting estrogen after anticoagulation completes is generally avoided — recurrence risk doubles.

— Stop after VTE; transdermal estrogen has lower (but not zero) VTE risk than oral if HRT is medically necessary.

— Thromboprophylaxis with LMWH antepartum if prior unprovoked or hormone-provoked VTE.

— Postpartum prophylaxis for 6 weeks in all women with prior VTE.

Board pearl: Pregnancy/postpartum is a major transient provoking factor — 3 months is sufficient, but anticoagulate through at least 6 weeks postpartum regardless of when in pregnancy the VTE occurred.

Pregnancy-associated VTE:

Postpartum:

Breastfeeding:

Combined hormonal contraception:

Hormone replacement therapy (HRT):

Future pregnancies after prior VTE:

Complications and Adverse Outcomes

— Annual major bleeding ~1–3% on DOACs, ~2–4% on warfarin.

— Sites: GI (most common), intracranial (most lethal), GU, retroperitoneal.

— Management:

— Hold anticoagulant.

— Supportive care: fluids, transfusion (target Hgb >7), reverse hypothermia/acidosis.

— Reversal: andexanet alfa (apixaban, rivaroxaban — limited availability, expensive), 4-factor PCC (off-label, widely used), idarucizumab (dabigatran), vitamin K + 4F-PCC (warfarin).

— 20–50% after proximal DVT; chronic edema, pain, ulceration.

— Prevention: early ambulation, adequate initial anticoagulation, graduated compression stockings (30–40 mmHg) — though SOX trial questioned routine use.

— Treatment: compression, pentoxifylline (limited), wound care.

— 2–4% after PE; dyspnea, fatigue, exercise intolerance.

— Screen with V/Q scan; confirm with right heart cath + CT-PA.

— Treat with pulmonary thromboendarterectomy (curative if accessible), riociguat, balloon pulmonary angioplasty.

— First, confirm diagnosis and adherence.

— Check drug levels (anti-Xa) and interactions.

— Switch from DOAC to LMWH; if on LMWH, increase dose by 25%.

— Evaluate for occult malignancy and APS.

— 4T score; stop heparin, start argatroban or fondaparinux; never give platelet transfusion.

Step 3 management: Major GI bleed on apixaban → hold drug, transfuse, andexanet alfa or 4F-PCC, GI consult for endoscopy. Resume anticoagulation in 7–14 days after source control, often at reduced dose or different agent.

Major bleeding (the dominant tradeoff in duration decisions):

Post-thrombotic syndrome (PTS):

Chronic thromboembolic pulmonary hypertension (CTEPH):

Recurrent VTE on therapy:

Heparin-induced thrombocytopenia (HIT):

When to Escalate Care — ICU, Consult, or Inpatient Triage

— SBP <90 mmHg for ≥15 min, vasopressors required, or cardiac arrest.

— ICU admission, systemic thrombolysis (alteplase 100 mg over 2 hours) or catheter-directed thrombolysis, consider ECMO.

— Pulmonary embolism response team (PERT) activation where available.

— Hemodynamically stable but RV strain on echo/CT or elevated troponin/BNP.

— Telemetry/step-down unit; consider catheter-directed therapy in selected patients (PEITHO, ULTIMA trials).

— Recurrent VTE on therapeutic anticoagulation.

— APS positive — confirm with repeat testing in 12 weeks.

— Unusual-site thrombosis.

— Suspected HIT, TTP, or myeloproliferative neoplasm.

— PESI class I–II or sPESI = 0: consider direct discharge from ED on DOAC.

— Requires reliable patient, no severe comorbidities, no significant bleeding risk, ability to follow up within 1 week.

— Hypoxia requiring oxygen, RV dysfunction, elevated troponin, social/access barriers, severe comorbidity, active bleeding risk needing observation.

— Only indication: acute proximal DVT or PE with absolute contraindication to anticoagulation (active major bleed, recent neurosurgery).

— Retrievable filter preferred; remove as soon as anticoagulation can be started.

— Not for routine "prophylaxis" or in addition to anticoagulation (PREPIC trials showed no mortality benefit, increased DVT).

CCS pearl: For massive PE with shock — order continuous telemetry, ICU bed, alteplase 100 mg IV over 2 hours, heparin drip after lytic, echocardiogram, troponin, BNP. Advance clock and reassess hemodynamics every 15 minutes initially.

Hemodynamic instability with acute PE (massive/high-risk PE):

Submassive/intermediate-risk PE:

Hematology consult:

Outpatient management of low-risk PE:

Inpatient indications:

IVC filter:

Key Differentials — Other Thrombotic Conditions

— Platelet drop >50% from baseline, 5–10 days after heparin exposure, with new thrombosis.

— 4T score ≥4 → send anti-PF4 antibodies, confirm with serotonin release assay.

— Switch to argatroban or fondaparinux; transition to warfarin only after platelets >150,000.

— Duration: 3 months if thrombosis present.

— Already addressed — clinical event + persistent (12 weeks apart) lab positivity.

— Indefinite warfarin INR 2–3.

— Unusual-site thrombosis (hepatic/splanchnic), hemolysis, cytopenias.

— Flow cytometry for CD55/CD59 deficiency.

— Treat with eculizumab; anticoagulate as long as PNH active.

— JAK2 V617F mutation.

— Splanchnic vein thrombosis is a classic clue.

— Treat underlying MPN + indefinite anticoagulation.

— Factor V Leiden (most common, heterozygous mildly increases risk), prothrombin G20210A, protein C/S deficiency, antithrombin deficiency (highest recurrence).

— Testing rarely changes duration decisions; positive results in unprovoked VTE just reinforce already-indicated indefinite therapy.

Key distinction: Heterozygous Factor V Leiden in a patient with provoked VTE does not justify extending anticoagulation beyond 3 months. Antithrombin deficiency or homozygous thrombophilias may, in selected patients.

Board pearl: A young woman with left-sided DVT, no provoking factors → consider May-Thurner; imaging shows iliac vein compression; treatment includes venous stenting.

Heparin-induced thrombocytopenia (HIT):

Antiphospholipid syndrome:

Paroxysmal nocturnal hemoglobinuria (PNH):

Myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia):

Inherited thrombophilias:

May-Thurner syndrome: left iliac vein compression by right iliac artery; young women with left-sided DVT. Treat with anticoagulation + stenting.

Key Differentials — Mimics of Recurrent VTE

Step 3 management: Patient on apixaban returns with new calf swelling at 4 months. Order duplex ultrasound — if it shows new thrombus extension, you have breakthrough VTE (check adherence, drug interactions, malignancy workup, switch to LMWH). If unchanged from baseline → likely PTS; manage with compression and continue current anticoagulation.

Key distinction: "Residual" thrombus on imaging is not recurrence — must show new non-compressible segment or extension of >9 mm in diameter to diagnose recurrent DVT.

Post-thrombotic syndrome flare: chronic leg swelling and pain mimic new DVT. Duplex shows old residual thrombus without new occlusion. Compare to baseline 3-month ultrasound.

Cellulitis: warmth, erythema with sharp borders, fever, leukocytosis; treat with antibiotics, not anticoagulation.

Baker's cyst rupture: sudden calf pain, "crescent sign" of ecchymosis below malleolus; ultrasound shows fluid tracking, no DVT.

Musculoskeletal strain or hematoma: especially on anticoagulation — suspect spontaneous intramuscular bleed.

Lymphedema: chronic, bilateral or asymmetric non-pitting edema; no acute onset.

Heart failure exacerbation: bilateral edema, dyspnea — distinguish from PE recurrence with BNP, CXR, echo.

Pneumonia or pleurisy: pleuritic chest pain and dyspnea mimicking recurrent PE; CXR, procalcitonin, CT-PA if uncertain.

Anxiety/panic attack: tachycardia, dyspnea — diagnosis of exclusion in patients with VTE history.

Pulmonary infarction late changes: residual perfusion defects on imaging may persist 6 months post-PE; do not over-treat asymptomatic abnormalities.

CT-PA artifact: respiratory motion, low contrast bolus → false-positive subsegmental PE; correlate clinically before extending therapy.

Secondary Prevention and Long-Term Plan

— Major transient provoking factor → 3 months, stop.

— Minor transient provoking factor → 3 months, reassess; consider extension if other risks.

— Unprovoked first VTE → at least 3–6 months; indefinite preferred if low-moderate bleeding risk; reduced-dose DOAC after 6 months.

— Recurrent unprovoked VTE → indefinite, full or reduced dose.

— Active cancer → indefinite while active; DOAC or LMWH.

— APS → indefinite warfarin INR 2–3.

— Weight loss if BMI >30 (obesity is a persistent VTE risk factor).

— Smoking cessation.

— Hydration and ambulation on long flights (>4 hours); compression stockings, walk every 1–2 hours.

— Avoid estrogen-containing contraceptives.

— Bleeding history this year? Major events?

— New medications (NSAIDs, antiplatelets, CYP/P-gp interactors)?

— Renal function (recalculate CrCl)?

— Cognition and adherence?

— Updated bleeding score.

— Confirm continued patient agreement.

Board pearl: Reduced-dose apixaban (2.5 mg BID) or rivaroxaban (10 mg daily) after 6 months of full-dose therapy is the standard for extended treatment of unprovoked VTE — equally effective, less bleeding.

Step 3 management: Document "shared decision-making conversation regarding indefinite anticoagulation conducted; patient understands recurrence vs bleeding tradeoff and elects to continue."

Anticoagulation duration summary (memorize this lattice):

Lifestyle and behavioral modification:

Vaccinations: influenza and pneumococcal — reduce hospitalization (and thus future VTE provocation).

Bone health: long-term LMWH (>6 months) risks osteoporosis; check DEXA if extended LMWH use.

Annual reassessment for patients on indefinite anticoagulation:

Follow-Up, Monitoring Parameters, and Counseling

— 2 weeks post-diagnosis: confirm symptom resolution, tolerance of anticoagulant, adherence.

— 1 month: review labs (CBC, CMP), check for bleeding, reassess function.

— 3 months: critical decision point — provoked vs unprovoked → continue or stop.

— 6 months: if continuing, consider step-down to reduced-dose DOAC.

— Annually thereafter: bleeding risk, renal function, medication reconciliation, fall risk, patient preference.

— DOACs: no routine coagulation monitoring; CBC and CMP every 6–12 months.

— Warfarin: INR weekly until stable, then every 4–12 weeks; target 2.0–3.0 (2.5–3.5 if APS with arterial events).

— LMWH: anti-Xa level rarely needed; check in pregnancy, obesity (BMI >40), or renal impairment.

— Take DOAC at the same time daily; rivaroxaban 15/20 mg with food.

— Never double up missed doses (apixaban: take if remembered same day; rivaroxaban: same).

— Avoid NSAIDs; use acetaminophen for pain.

— Medical alert bracelet.

— Notify all providers (dentist, surgeon) before procedures — DOAC hold typically 1–2 days pre-procedure (longer if renal impairment or high bleeding risk).

— Recognize bleeding warning signs: melena, hematuria, severe headache, unexplained bruising.

— Graduated return to activity; pulmonary rehab if persistent functional limitation.

— Repeat echo at 3–6 months if initial RV dysfunction.

CCS pearl: At 3-month visit on the CCS, order — CBC, CMP, clinical reassessment, decision documentation; do not order routine D-dimer or thrombophilia panel unless specifically indicated.

Follow-up cadence:

Monitoring labs:

Patient counseling points:

Rehab/functional recovery post-PE:

Ethical, Legal, and Patient Safety Considerations

— Discuss in clear terms: ~10%/year recurrence off therapy vs ~1–3%/year major bleeding on therapy.

— Use shared decision-making aids when available (Mayo VTE Choice tool).

— Document patient preferences, especially regarding risk tolerance for catastrophic bleeding (ICH) vs catastrophic clotting (fatal PE).

— Hospital discharge on anticoagulation is a sentinel safety event. Provide:

— Written stop date or "indefinite" plan.

— Follow-up appointment within 7 days.

— Pharmacy education and a 30-day supply.

— Reconciliation with home medications (especially antiplatelets, NSAIDs).

— Many recurrent VTE and bleeding events stem from miscommunication at care transitions.

— DOACs are involved in a disproportionate share of inpatient adverse drug events.

— Standardize CrCl-based dosing checks; use EHR alerts.

— Beware "stealth" interactions: amiodarone, dronedarone, verapamil, ketoconazole, rifampin.

— Establish a clear hold-and-resume plan; communicate with proceduralist.

— Bridging with LMWH is rarely needed for DOACs (short half-life) and usually unnecessary for warfarin except in mechanical valves or recent VTE (<3 months).

— Patients with cognitive impairment or unstable housing may not safely manage anticoagulation — involve caregivers, pill organizers, or consider warfarin with anticoagulation clinic oversight.

Step 3 management: Pre-colonoscopy, hold apixaban 1–2 days (CrCl >50); resume 24 hours after low-bleeding-risk procedure, 48–72 hours after high-bleeding-risk procedure. No bridging.

Board pearl: Bridging anticoagulation increases bleeding without reducing thrombosis (BRIDGE trial) — don't bridge unless mechanical mitral valve, recent VTE <3 months, or CHA2DS2-VASc very high.

Informed consent for indefinite anticoagulation:

Transitions of care — high-risk handoffs:

Medication safety:

Periprocedural management:

Capacity and adherence:

Disclosure of error: if a missed VTE diagnosis or anticoagulation error occurs, disclose to the patient promptly — ethically required and supported by patient-safety culture.

High-Yield Associations and Rapid-Fire Clinical Facts

Board pearl: "Indefinite" ≠ "forever without review." Reassess bleeding-clotting balance every year, every new hospitalization, and every new medication.

3 months is the minimum; the question is always "stop or continue?"

Male sex doubles recurrence risk after unprovoked VTE vs female.

Elevated D-dimer 1 month after stopping anticoagulation predicts recurrence.

HERDOO2 ≤1: only validated rule to identify women safe to stop.

Cancer-associated VTE: apixaban, edoxaban, or rivaroxaban first-line; LMWH if luminal GI/GU cancer.

Antiphospholipid syndrome: warfarin only, never DOAC, especially triple-positive.

Pregnancy: LMWH only; continue ≥6 weeks postpartum.

Splanchnic vein thrombosis: check JAK2 for occult MPN.

Reduced-dose DOAC (apixaban 2.5 BID, rivaroxaban 10 daily) after 6 months — extended therapy standard.

Aspirin reduces recurrence ~30% — inferior backup if anticoagulation refused.

IVC filter only when anticoagulation is absolutely contraindicated; remove ASAP.

CTEPH screen = V/Q scan, not CT-PA.

Subsegmental PE without DVT in low-risk patient → surveillance acceptable.

Isolated distal DVT → either 6-week anticoagulation or 2-week surveillance ultrasound.

Post-thrombotic syndrome: 20–50% after proximal DVT.

Bridging is dead for most DOAC and warfarin holds (BRIDGE trial).

Andexanet alfa for apixaban/rivaroxaban major bleed; idarucizumab for dabigatran.

Estrogen contraception must stop after VTE — switch to progestin-only or non-hormonal.

JAK2 V617F, PNH, APS, occult cancer — the four "don't miss" workups in unprovoked VTE at unusual sites.

Annual reassessment required for all patients on indefinite anticoagulation.

DOACs preferred over warfarin for most VTE — fewer ICH, equal efficacy.

Board Question Stem Patterns

— Answer: Continue anticoagulation indefinitely (typically step down to rivaroxaban 10 mg daily); assess bleeding risk; document shared decision-making. Male sex + unprovoked = high recurrence.

— Answer: 3 months, discontinue OCPs, switch to non-estrogen contraception. Major transient provoking factor.

— Answer: Step down to apixaban 2.5 mg BID indefinitely, annual reassessment.

— Answer: APS — warfarin INR 2–3 indefinitely; DOACs contraindicated.

— Answer: Apixaban or LMWH, continue indefinitely as long as cancer is active. Avoid rivaroxaban if GI luminal involvement.

— Answer: Enoxaparin therapeutic dose; continue through pregnancy + at least 6 weeks postpartum; avoid warfarin and DOACs.

— Answer: Hold apixaban, transfuse, andexanet alfa or 4F-PCC, GI endoscopy, reassess anticoagulation after source control.

— Answer: V/Q scan to screen for CTEPH; echocardiogram for RV function.

— Answer: Consider May-Thurner syndrome; cross-sectional imaging of iliac veins; possible venous stenting.

Key distinction: Question stems hinge on identifying the provocation category and the bleeding tradeoff — those two variables, almost always, determine the right answer.

"55-year-old man with unprovoked PE completes 3 months of rivaroxaban. Next step?"

"35-year-old woman with DVT 2 weeks after knee surgery, on OCPs. Anticoagulation duration?"

"68-year-old man with unprovoked DVT completes 6 months of apixaban 5 mg BID. CrCl 45. How to manage?"

"42-year-old woman with recurrent DVT, prolonged aPTT, history of two miscarriages. Anticoagulation choice?"

"60-year-old with metastatic pancreatic cancer develops PE on chemotherapy. Anticoagulation?"

"30-year-old G2P1 at 28 weeks with new DVT. Treatment?"

"72-year-old on apixaban 5 mg BID for unprovoked PE has melena, Hgb 6.8. Management?"

"45-year-old man, persistent dyspnea 4 months post-PE, on apixaban. Next step?"

"Young woman with left iliofemoral DVT, no risk factors."

One-Line Recap

Every VTE patient gets at least 3 months of anticoagulation; the durable decision is whether to continue indefinitely, and that decision rests on whether the event was provoked (stop), unprovoked (extend, usually with reduced-dose DOAC), or driven by a persistent risk factor like cancer or antiphospholipid syndrome (indefinite).

— Major transient provocation (surgery, hospitalization, trauma, cesarean) → 3 months, stop.

— Unprovoked first VTE → ≥3–6 months; favor indefinite at reduced dose if bleeding risk is acceptable.

— Recurrent or persistent risk factor (cancer, APS, MPN) → indefinite.

— Pregnancy/postpartum → LMWH through delivery + ≥6 weeks postpartum (≥3 months total).

— DOACs are first-line for nearly all VTE; apixaban has the best safety profile.

— Warfarin only for APS, mechanical valves, severe renal impairment.

— LMWH for pregnancy and selected cancer patients.

— Reduced-dose apixaban (2.5 mg BID) or rivaroxaban (10 mg daily) is the extended-therapy standard.

— Reassess bleeding risk and renal function annually.

— Stop estrogen, document shared decision-making.

— Hold for procedures with short, simple plans — no bridging in most cases.

— Screen for CTEPH (V/Q) and post-thrombotic syndrome on follow-up.

Board pearl: When a stem ends with "3 months of anticoagulation have been completed — what next?" — your answer is almost always determined by one question: Was the index event provoked by a major transient factor? If yes, stop. If no, extend, usually at reduced dose, with annual reassessment and shared decision-making documented.

The lattice:

The agents:

The safety nets: